Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
Andrea
A
Calcagno
Stefano
S
Bonora
Maria Cristina
MC
Tettoni
Antonio
A
D'Avolio
Giovanni Di
GD
Perri
Massimiliano
M
Lanzafame
Giovanni
G
Penco
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D049670:History, 17th Century; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D063065:Organophosphonates / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D009842:Oligopeptides; D063065:Organophosphonates; D011725:Pyridines; D000069446:Atazanavir Sulfate; D000068698:Tenofovir; D000225:Adenine